Search

Your search keyword '"Li, Ye-Xiong"' showing total 29 results
Start Over Author "Li, Ye-Xiong" Journal international journal of radiation oncology, biology, physics
29 results on '"Li, Ye-Xiong"'

1. Dose-Volume Predictors for Radiation Esophagitis in Patients With Breast Cancer Undergoing Hypofractionated Regional Nodal Radiation Therapy

Author

Wang, Dan-Qiong, Zhang, Na, Dong, Li-Hua, Zhong, Ya-Hua, Wu, Hong-Fen, Zhong, Qiu-Zi, Jin, Jing, Hou, Xiao-Rong, Jing, Hao, Tang, Yu, Hu, Chen, Song, Yong-Wen, Liu, Yue-Ping, Qi, Shu-Nan, Tang, Yuan, Lu, Ning-Ning, Chen, Bo, Zhai, Yi-Rui, Zhang, Wen-Wen, Li, Ning, Fang, Hui, Li, Ye-Xiong, and Wang, Shu-Lian

Published
2023
Full Text
View/download PDF

9. Patterns of Primary Tumor Invasion and Regional Lymph Node Spread Based on Magnetic Resonance Imaging in Early-Stage Nasal NK/T-cell Lymphoma: Implications for Clinical Target Volume Definition and Prognostic Significance

Author

Wu, Run-Ye, Liu, Kang, Wang, Wei-Hu, Jin, Jing, Song, Yong-Wen, Wang, Shu-Lian, Liu, Yue-Ping, Ren, Hua, Fang, Hui, Liu, Qing-Feng, Yang, Yong, Chen, Bo, Qi, Shu-Nan, Lu, Ning-Ning, Tang, Yu, Tang, Yuan, Li, Ning, Ouyang, Han, and Li, Ye-Xiong

Published
2017
Full Text
View/download PDF

25. Phase I Study of Oxaliplatin in Combination With Capecitabine and Radiotherapy as Postoperative Treatment for Stage II and III Rectal Cancer

Author

Jin, Jing, Li, Ye-Xiong, Wang, Jin-Wan, Wang, Wei-Hu, Liu, Yue-Ping, Wang, Kai, Fang, Hui, Zhou, Zhi-Xiang, Zhou, Ai-Ping, and Yu, Zi-Hao

Subjects
*OXALIPLATIN, *RADIOTHERAPY, *POSTOPERATIVE care, *RECTAL cancer
Abstract

Purpose: A Phase I study was conducted to determine the maximal tolerated dose and the dose-limiting toxicity (DLT) of oxaliplatin (OXA) combined with capecitabine and radiotherapy as adjuvant treatment in patients with operable rectal cancer. Patients and Methods: A total of 21 patients with Stage II or III rectal adenocarcinoma after curative surgery were treated with radiotherapy to a total dose of 50 Gy in 5 weeks. OXA was administered at a dosage of 40 (n = 6), 50 (n = 3),60 (n = 3), 70 (n = 3), or 80 mg/m2 (n = 6) once a week for 2 weeks (first cycle) followed by a second cycle after a 7-day break. Capecitabine at a fixed dose of 1,300 mg/m2/d was administered orally at the same schedule as for OXA. DLT was defined as Grade 3 or 4 hematologic and nonhematologic toxicity. Results: Grade 1–3 leukopenia, diarrhea, and nausea/vomiting were the most common toxic side effects, and most were Grade 1-2. A DLT was first observed in 1 of 3 patients at 40 mg/m2 (Grade 3 diarrhea) but was not observed in the next 3 patients at the same level or in patients who received a dose level of 50–70 mg/m2. At 80 mg/m2, DLT occurred in 3 of 6 patients (1 Grade 4 leukopenia and 2 Grade 3 diarrhea). Conclusions: OXA combined with a fixed dose of capecitabine at 625 mg/m2 twice daily by mouth plus radiotherapy in the adjuvant setting was tolerable and clinically feasible. The maximal tolerated dose of OXA in this setting was 80 mg/m2, comparable to the maximal tolerated dose of OXA in the neoadjuvant setting. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

26. A Phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer

Author

Jin, Jing, Li, Ye-Xiong, Liu, Yue-Ping, Wang, Wei-Hu, Song, Yong-Wen, Li, Tao, Li, Ning, Yu, Zi-Hao, and Liu, Xin-Fan

Subjects
*CANCER treatment, *ADJUVANT treatment of cancer, *RECTAL cancer, *DRUG therapy, *MEDICAL radiology
Abstract

Purpose: To determine the maximum tolerated dose and the dose-limiting toxicity of capecitabine with standard radiotherapy (RT) as adjuvant treatment in patients with rectal cancer. Methods and Materials: Patients with Stage II/III rectal cancer after surgery were eligible. Total RT dose was delivered as DT 50 Gy in fractions of 2.0 Gy/day for 5 weeks to the pelvic area. Capecitabine was administered concurrently with RT in escalating doses, twice daily with a 12-h interval, for two cycles of 14 days separated by a 7-day rest. Dose-limiting toxicity included Grade 3 or Grade 4 hematologic and nonhematologic toxicity. Results: Twenty-four patients were enrolled at the following dose levels: 1,000 (3 patients), 1,200 (3 patients), 1,400 (3 patients), 1,500 (3 patients), 1,600 (6 patients), and 1,700 mg/m2/day (6 patients). Dose-limiting toxicity was observed in 1 patient at 1,600 mg/m2/day (Grade 3 diarrhea) and in 2 patients at 1,700 mg/m2/day (1 patient had Grade 3 and 1 Grade 4 diarrhea). Conclusion: The maximum tolerated dose (MTD) of capecitabine given concurrently with RT was 1,600 mg/m2, daily from the 1st to the 14th day, with a 7-day rest, for two cycles. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results